Compound: Saralasin
SMILES: O=C(N[C@H](C(=O)O)C)[C@H]1N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC)CCCN=C(N)N)C(C)C)Cc2ccc(O)cc2)C(C)C)Cc3[nH]cnc3)CCC1
InChIKey: PFGWGEPQIUAZME-NXSMLHPHSA-N
Synonyms: Saralasin, 34273-10-4, Saralasina, Saralasine, Saralasinum, Sar-Arg-Val-Tyr-Val-His-Pro-Ala, DTXSID2046549, H2AFV2HE66, 1-Sar-8-Ala-angiotensin II, DTXCID0026549, (2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]propanoic acid, Angiotensin II, 1-(N-methylglycine)-5-L-valine-8-L-alanine-, (Sar(1),Ala(8))ANGII, (2S)-2-(((2S)-1-((2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-5-(diaminomethylideneamino)-2-((2-(methylamino)acetyl)amino)pentanoyl)amino)-3-methylbutanoyl)amino)-3-(4-hydroxyphenyl)propanoyl)amino)-3-methylbutanoyl)amino)-3-(1H-imidazol-5-yl)propanoyl)pyrrolidine-2-carbonyl)amino)propanoic acid, RefChem:884577, Hydrated Saralasin Acetate, Anhydrous Saralasin Acetate, Saralasin Acetate, Hydrated, 1 Sar 8 Ala Angiotensin II, 1-Sar-8-Ala Angiotensin II, Angiotensin II, 1-Sar-8-Ala, (Sar1,Val5,Ala8)Angiotensin II, 2-((1-(2-((2-((2-((2-((5-(diaminomethylideneamino)-2-((2-methylaminoacetyl)amino)pentanoyl)amino)-3-methylbutanoyl)amino)-3-(4-hydroxyphenyl)propanoyl)amino)-3-methylbutanoyl)amino)-3-(3H-imidazol-4-yl)propanoyl)pyrrolidine-2-carbonyl)amino)propanoic acid, angiotensin II, Sar(1)-Ala(8)-, 1 Sarcosine 8 Alanine Angiotensin II, 1-Sarcosine-8-Alanine Angiotensin II, Angiotensin II, 1-Sarcosine-8-Alanine, angiotensin II, sarcosyl(1)-alanine(8)-, (Sar1,Val5,Ala8)-Angiotensin II, CHEMBL938, C42H65N13O10, Saralasinum [INN-Latin], Saralasin [INN:BAN], Saralasine [INN-French], Saralasina [INN-Spanish], UNII-H2AFV2HE66, NCGC00166135-01, MFCD00167510, SCHEMBL23, SCHEMBL24, orb1679421, SCHEMBL29481947, CHEBI:135894, (1-(N-Methylglycin) 5-L-valin, 8-L-alanin)angiotensin II, HY-P0205, Tox21_112332, BDBM50009338, BDBM50229504, AKOS024456428, DB06763, NCGC00167316-01, FS108389, N-(1-(N-(N-(N-(N-(N2-(N-methylglycly)-L-arginyl)-L-valyl)-L-tyrosyl)-L-valyl)-L-histidyl)-L-prolyl)-L-alanine, CAS-34273-10-4, CS-0021297, NS00073478, Sar-Arg-Val-Tyr-Val-His-Pro-Ala (sarlasin), [Sar1-Arg2-Val3-Tyr4-Val5-His6-Pro7-Ala8], Q410298, (Sar 1,Val5,Ala8)-Angiotensin II trifluoroacetate salt, Sar-Arg-Val-Tyr-Val-His-Pro-Ala-OH trifluoroacetate salt, N-Methylglycyl-L-arginyl-L-valyl-L-tyrosyl-L-valyl-L-histidyl-L-prolyl-L-alanine, (2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-guanidino-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methyl-butanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methyl-butanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]propanoic acid, (S)-2-((S)-1-((S)-2-((S)-2-((S)-2-((S)-2-((S)-5-(diaminomethyleneamino)-2-(2-(methylamino)acetamido)pentanamido)-3-methylbutanamido)-3-(4-hydroxyphenyl)propanamido)-3-methylbutanamido)-3-(1H-imidazol-5-yl)propanoyl)pyrrolidine-5-carboxamido)propanoic acid
Theoretical properties:
molecular_formula: C42H65N13O10
molecular_weight: 912.0 g/mol
exact_mass: 911.49773532 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 12
hydrogen_bond_acceptor_count: 13
rotatable_bond_count: 25
heavy_atom_count: 65
topological_polar_surface_area: 358 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Saralasin is an oligopeptide.
chembl: SARALASIN is a protein listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Saralasin is a competitive angiotensin II receptor antagonist with partial agonistic activity. The aminopeptide sequence for saralasin differs from angiotensin II at three sites:

At position 1, sarcosine replaces aspartic acid, thereby increasing the affinity for vascular smooth muscle AT II receptors and making sara resistant to degradation by aminopeptidases.
At position 5, isoleucine is replaced by valine
At position 8, phenylalanine is replaced by alanine which leads to a smaller stimulatory effect. Saralasin was used to distinguish renovascular hypertension from essential hypertension before its discontinuation in January 1984 because of many false-positive and false-negative reports.